DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/qgwww7/asiapacific) has announced the addition of the "Asia-Pacific Nuclear Medicine Market - Trends And Forecasts (2014-2020)" report to their offering.
Asia-pacific nuclear medicine market was valued at $480.5 million in 2012 and is expected to reach $853 million in 2019 with a healthy CAGR of 10.6%
One of the popular forms of medical specialty, nuclear medicines involves application of radioactive substances in treatment of various diseases and disorders. Also known as radiopharmaceuticals, these drugs contain radio-emitting ionization radiation and help in diagnosing disease and provide suitable treatment. Accurate identification and treatment of the disease are two major advantages of the nuclear medicine.
Rising demand and evolving technology in the healthcare industry are the strongest driving factors for the global nuclear medicine market, which is aiming at steady growth in terms of revenue and global adoption. Increasing use of SPECT and PET technology for the treatment of the diseases propels market to grow further. Persistent side effects of cancer chemotherapy and radiation therapy are also the driving factors for the market. However, market is constrained by short half life of the radioisotopes which make them difficult to use.
Asia-Pacific nuclear medicine market is segmented by Therapeutic market and Diagnostic market. Both these segments are further categorized based on the types of medicines, their applications and demands. Based on these segments, experts claim that the therapeutic market is mainly dominated by beta emitters for oncology applications. Diagnostic market on the other hand is dominated by radioisotopes such as SPECT and PET. Based on countries, market is segmented into India, China and Japan. Japan is the dominant market for diagnostic radioisotopes with almost 40% share and has around 1,600 gamma cameras. The total number of PET institutes in Japan has increased around 6-7 times in the last 10 years.
Major players in the market are Covidien, IBA Group, Lantheus Medical Imaging, Triad Isotopes, Siemens Healthcare (PETNET Solutions), NTP Radioisotopes.
Key Topics Covered:
1. Introduction
2. Executive Summary
3. Market Overview
4. Market Dynamics
5. Asia-Pacific Nuclear Medicine Market Segmentation
6. Nuclear Medicine Market, By Type Of Products
7. Diagnostic Market, By Applications
8. Others
9. Competitive Landscape
10. Top Players In The Market
Companies Featured:
- Bracco Imaging S.P.A.
- Cambridge Isotope Laboratories, Inc.
- Cardinal Health, Inc
- Covidien, Plc
- Eczacibasi-Monrol
- Fujifilm Holdings Corporation
- GE Healthcare (Subsidiary Of General Electric Company)
- Iba Group
- Isotec, Inc. (Sigma-Aldrich)
- Lantheus Medical Imaging, Inc.
- Nordion, Inc.
For more information visit http://www.researchandmarkets.com/research/qgwww7/asiapacific
